Valiant Laboratories Limited
NSEI:VALIANTLAB Rapporto sulle azioni
Valiant Laboratories Salute del bilancio
Salute finanziaria criteri di controllo 3/6 Valiant Laboratories ha un patrimonio netto totale di ₹2.4B e un debito totale di ₹767.1M, che porta il suo rapporto debito/patrimonio netto a 32.4%. Le sue attività totali e le sue passività totali sono rispettivamente ₹3.4B e ₹1.1B.
Informazioni chiave
32.4%
Rapporto debito/patrimonio netto
Indice di copertura degli interessi n/a Contanti ₹1.44b Patrimonio netto ₹2.37b Totale passività ₹1.06b Totale attività ₹3.43b
Aggiornamenti recenti sulla salute finanziaria
Mostra tutti gli aggiornamenti
Valiant Laboratories Limited to Report Q2, 2025 Results on Nov 12, 2024 Nov 08
Valiant Laboratories Limited to Report Q1, 2025 Results on Aug 12, 2024 Aug 06
Full year 2024 earnings released: EPS: ₹0.084 (vs ₹8.91 in FY 2023) Jul 23
Does Valiant Laboratories (NSE:VALIANTLAB) Have A Healthy Balance Sheet? Jul 20
Valiant Laboratories Limited, Annual General Meeting, Aug 08, 2024 Jul 18 Valiant Laboratories Limited, Annual General Meeting, Aug 08, 2024 Jul 16
New major risk - Earnings quality May 16
Full year 2024 earnings released: EPS: ₹0.13 (vs ₹13.36 in FY 2023) May 16
Valiant Laboratories Limited Appoints Prajakta Patil as the Company Secretary and Compliance Officer May 16
Now 21% undervalued after recent price drop May 15
Valiant Laboratories Limited Appoints Prajakta Patil as the Company Secretary and Compliance Officer May 15
Valiant Laboratories Limited to Report Q4, 2024 Results on May 14, 2024 May 09
High number of new and inexperienced directors Mar 31 Valiant Laboratories Limited Announces Resignation of Saloni Mehta as Company Secretary & Compliance Officer, with effect from close of business hour on March 31, 2024 Mar 30
Now 20% undervalued after recent price drop Mar 13
New major risk - Revenue and earnings growth Feb 12
Third quarter 2024 earnings released Feb 12
Valiant Laboratories Limited to Report Q3, 2024 Results on Feb 09, 2024 Feb 02
Investor sentiment improves as stock rises 17% Jan 19
New major risk - Earnings quality Nov 16 Valiant Laboratories Limited to Report Q2, 2024 Results on Nov 06, 2023 Oct 31
Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( ₹2.3B ) di VALIANTLAB superano le sue passività a breve termine ( ₹290.8M ).
Passività a lungo termine: Le attività a breve termine di VALIANTLAB ( ₹2.3B ) superano le sue passività a lungo termine ( ₹767.5M ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: VALIANTLAB ha più liquidità del suo debito totale.
Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di VALIANTLAB si sia ridotto negli ultimi 5 anni.
Copertura del debito: Il debito di VALIANTLAB non è ben coperto dal flusso di cassa operativo ( 2.5% ).
Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di VALIANTLAB siano ben coperti dall' EBIT .
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
